Anebulo Pharmaceuticals Inc. (NASDAQ: ANEB) has confirmed that it will release its Q4 2021 earnings on Monday, September 20, 2021.
What to look for
Recently the company completed an IPO raising gross proceeds of $20.2 million from the issuance of 3.078 shares. According to the management, the net proceeds from the IP are adequate to fund operations through the end of 2022. Most notably, the company commenced its second phase proof of concept ANEB-001 clinical study for cannabinoid overdose in Q4 2021, with results expected in 1H 2022.
Earnings: Stockearning’s estimated EPS for Q4 2021 is a loss of $0.03 per share. Historical earnings per share performance for the past 12 quarters show the company beat estimates zero times (0%0 and missed estimates zero times (0%). In the most recent quarter, the company reported a net loss of $0.7 per share.
Revenue: At the end of Q3, the company had cash of $3.3 million, and net loss was $555,832 or $0,04 per share. Net loss attributable to shareholders was $8.76 million or $0.69 per share, including preferred shares dividends of $8.208 million.
Stock movement: Since the last earnings release, the stock has lost 5.5% to the previous closing price of $6.9. Following earnings releases, ANEB share price has been DOWN 1 time in the past one quarter. So, Historical price movement suggests that there is a 100% chance that the stock will drop. According to the Stockearning algorithm, the predicted first-day move of the stock is 4$, while the expected move on the seventh day is 4%.
What analysts are saying
Anebulo Pharmaceuticals was given a “Buy” rating and a price target of $15 by Benchmark analyst Robert Wasserman. Wasserman tells investors that the company is exploring unique solutions for persons suffering from substance addiction and cannabis overdose. His price target is based on a comparison of the company's flagship candidate, ANEB-001, with other equities in the substance abuse sector.
Related News:
Apogee Enterprises Inc. (NASDAQ: APOG) Earnings Expectation, 50% Chance to Top Estimates.
Lennar Corporation (NYSE: LEN) Expects Q3 2021 Earnings Of $3.24 Per Share.
Manchester United Plc (NYSE: MANU) Earning Expectation, 58% Chance for the Stock price to Fall.